Allergan to sell women's health, infectious disease businesses to stop stock slide — 4 insights

Allergan will sell its women's health and infectious disease units to focus on its core portfolio offerings in an effort to increase shareholder value, Reuters reports.

Here's what you should know:

1. Allergan CEO Brent Saunders is focusing on the company's medical aesthetics, central nervous system, eye care and gastrointestinal lines.

2. The company has been losing value hand over fist since July 2017. To date, Allergan's stock has dropped 40.93 percent.

3. Allergan's board has considered a bevy of options like splitting the company or making acquisitions, but selling the two non-core offerings was the only unanimous decision.

4. RBC Capital Markets analyst Randall Stanicky believes the infectious disease business is worth around $1.5 billion, while the women's health business is worth $3 billion.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast